Thrombocytopenia · glioblastoma in adults
Anti‐EGFR therapy showed no clear difference in thrombocytopenia compared with placebo or standard of care (low certainty).
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with UFH prophylaxis (moderate certainty).
1 finding from 1 review
Thrombocytopenia · People with cancer with perioperative thromboprophylaxis
LMWH prophylaxis showed no clear difference in thrombocytopenia compared with fondaparinux prophylaxis (low certainty).
1 finding from 1 review
Thrombocytopenia
Heparin prophylaxis showed no clear difference in thrombocytopenia compared with no prophylaxis (moderate certainty).
1 finding from 1 review
Intervention not reported
Thrombocytopenia (grade 3/4) · women with newly diagnosed EOC (stage Ic to IV)
The intervention leads to higher thrombocytopenia (grade 3/4) (high certainty).
1 finding from 1 review
Thrombocytopenia · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with the initial treatment of venous thromboembolism in patients with cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · patients with active cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thrombocytopenia · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) showed no clear difference in thrombocytopenia (up to 3 months) compared with no LMWH (low certainty).
1 finding from 1 review
Thrombocytopenia (up to 3 months)n · people with cancer with thrombosis prophylaxis and central venous catheters
Low‐molecular‐weight heparin (LMWH) probably leads to higher thrombocytopenia (up to 3 months)n compared with vitamin K antagonist (VKA) (moderate certainty).
1 finding from 1 review
Thrombocytopenia (main analysis‐ active cancer) · patients with cancer with venous thromboembolism
Low molecular weight heparin secondary prophylaxis showed no clear difference in thrombocytopenia (main analysis‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review